References
1. Vandrey R, Dunn KE, Fry JA, Girling ER. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend 2012;120(1-3):238-41.
2. Varga K, Wagner JA, Bridgen DT, Kunos GJTFj. Platelet‐and macrophage‐derived endogenous cannabinoids are involved in endotoxin‐induced hypotension. 1998;12(11):1035-1044.
3. Pacher P, Bátkai S, Kunos GJPr. The endocannabinoid system as an emerging target of pharmacotherapy. 2006;58(3):389-462.
4. Ashton JC, Smith PFJCvp. Cannabinoids and cardiovascular disease: the outlook for clinical treatments. 2007;5(3):175-184.
5. Pacher P, Mukhopadhyay P, Mohanraj R, Godlewski G, Bátkai S, Kunos GJH. Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. 2008;52(4):601-607.
6. Goyal H, Awad HH, Ghali JKJJotd. Role of cannabis in cardiovascular disorders. 2017;9(7):2079.
7. Pacher P, Steffens S. The emerging role of the endocannabinoid system in cardiovascular disease. 2009. Springer. p 63-77.
8. Nelson MA. MECHANISMS OF SYNTHETIC CANNABINOIDS ON CARDIOVASCULAR HEALTH. 2021.
9. Mir A, Obafemi A, Young A, Kane C. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 2011;128(6):e1622-7.
10. Young AC, Schwarz E, Medina G, Obafemi A, Feng SY, Kane C, Kleinschmidt K. Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med 2012;30(7):1320.e5-7.
11. Su MK, Seely KA, Moran JH, Hoffman RS. Metabolism of classical cannabinoids and the synthetic cannabinoid JWH-018. Clin Pharmacol Ther 2015;97(6):562-4.
12. Cooper ZD. Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal. Curr Psychiatry Rep 2016;18(5):52.
13. Zou S, Kumar U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. International journal of molecular sciences 2018;19(3):833.
14. Bonz A, Laser M, Küllmer S, Kniesch S, Babin-Ebell J, Popp V, Ertl G, Wagner JA. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol 2003;41(4):657-64.
15. Rajesh M, Bátkai S, Kechrid M, Mukhopadhyay P, Lee WS, Horváth B, Holovac E, Cinar R, Liaudet L, Mackie K and others. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Diabetes 2012;61(3):716-27.
16. Sugiura T, Kodaka T, Nakane S, Kishimoto S, Kondo S, Waku K. Detection of an endogenous cannabimimetic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator? Biochem Biophys Res Commun 1998;243(3):838-43.
17. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995;232(1):54-61.
18. Niederhoffer N, Schmid K, Szabo B. The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression. Naunyn Schmiedebergs Arch Pharmacol 2003;367(5):434-43.
19. Czeisler M, Lane RI, Petrosky E, Wiley JF, Christensen A, Njai R, Weaver MD, Robbins R, Facer-Childs ER, Barger LK and others. Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic - United States, June 24-30, 2020. MMWR Morb Mortal Wkly Rep 2020;69(32):1049-1057.
20. Chung EY, Cha HJ, Min HK, Yun J. Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists. Arch Pharm Res 2021;44(4):402-413.
21. Tai S, Fantegrossi WE. Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites. Current topics in behavioral neurosciences 2017;32:249-262.
22. Schoeder CT, Hess C, Madea B, Meiler J, Müller CE. Pharmacological evaluation of new constituents of “Spice”: synthetic cannabinoids based on indole, indazole, benzimidazole and carbazole scaffolds. Forensic Toxicology 2018;36(2):385-403.
23. Eid BG. Cannabinoids for Treating Cardiovascular Disorders: Putting Together a Complex Puzzle. Journal of microscopy and ultrastructure 2018;6(4):171-176.
24. Banister SD, Stuart J, Kevin RC, Edington A, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Hibbs DE, Glass M and others. Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chem Neurosci 2015;6(8):1445-58.
25. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, Group NCRRGW. Animal research: reporting in vivo experiments: the ARRIVE guidelines. British journal of pharmacology 2010;160(7):1577-1579.
26. Walker MJA, Curtis M, Hearse DJ, Campbell RWF, Riva E, Janse M, Yellon DM, Cobbe SM, Coker SJ, Harness JB and others. The Lambeth Conventions: Guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. Cardiovascular research 1988;22:447-55.
27. Bentli R, Parlakpinar H, Polat A, Samdanci E, Sarihan ME, Sagir M. Molsidomine prevents cisplatin-induced hepatotoxicity. Arch Med Res 2013;44(7):521-8.
28. Poklis JL, Amira D, Wise LE, Wiebelhaus JM, Haggerty BJ, Lichtman AH, Poklis A. Determination of naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in mouse blood and tissue after inhalation exposure to ’buzz’ smoke by HPLC/MS/MS. Biomed Chromatogr 2012;26(11):1393-8.
29. Poklis JL, Amira D, Wise LE, Wiebelhaus JM, Haggerty BJ, Poklis A. Detection and disposition of JWH-018 and JWH-073 in mice after exposure to ”Magic Gold” smoke. Forensic science international 2012;220(1-3):91-96.
30. O’Sullivan SE. Endocannabinoids and the Cardiovascular System in Health and Disease. Handb Exp Pharmacol 2015;231:393-422.
31. Ozturk HM, Yetkin E, Ozturk S. Synthetic Cannabinoids and Cardiac Arrhythmia Risk: Review of the Literature. Cardiovasc Toxicol 2019;19(3):191-197.
32. Von Der Haar J, Talebi S, Ghobadi F, Singh S, Chirurgi R, Rajeswari P, Kalantari H, Hassen GW. Synthetic Cannabinoids and Their Effects on the Cardiovascular System. J Emerg Med 2016;50(2):258-62.
33. Parlakpinar H, Celbis O, Ozhan O, Petekkaya S, Samdanci E, Ermis N, Koparir P, Soylu O, Acet A. Cardiovascular effects of JWH-018 from synthetic cannabinoids. 2016.
34. Lake KD, Compton DR, Varga K, Martin BR, Kunos G. Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther 1997;281(3):1030-7.
35. Hillard CJ. Endocannabinoids and vascular function. J Pharmacol Exp Ther 2000;294(1):27-32.
36. Ford WR, Honan SA, White R, Hiley CR. Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br J Pharmacol 2002;135(5):1191-8.
37. Varga K, Lake KD, Huangfu D, Guyenet PG, Kunos G. Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension 1996;28(4):682-6.
38. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Böhme GA, Imperato A, Pedrazzini T, Roques BP and others. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999;283(5400):401-4.
39. Bátkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J, Offertáler L, Mackie K, Rudd MA, Bukoski RD and others. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 2004;110(14):1996-2002.
40. Ishac EJ, Jiang L, Lake KD, Varga K, Abood ME, Kunos G. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol 1996;118(8):2023-8.
41. Malinowska B, Godlewski G, Bucher B, Schlicker E. Cannabinoid CB1 receptor-mediated inhibition of the neurogenic vasopressor response in the pithed rat. Naunyn Schmiedebergs Arch Pharmacol 1997;356(2):197-202.
42. Wagner JA, Járai Z, Bátkai S, Kunos G. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol 2001;423(2-3):203-10.
43. Vidrio H, Sánchez-Salvatori MA, Medina M. Cardiovascular effects of (-)-11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl in rats. J Cardiovasc Pharmacol 1996;28(2):332-6.
44. Pacher P, Bátkai S, Kunos G. Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice. J Physiol 2004;558(Pt 2):647-57.
45. Al Kury LT, Voitychuk OI, Yang KH, Thayyullathil FT, Doroshenko P, Ramez AM, Shuba YM, Galadari S, Howarth FC, Oz M. Effects of the endogenous cannabinoid anandamide on voltage-dependent sodium and calcium channels in rat ventricular myocytes. Br J Pharmacol 2014;171(14):3485-98.
46. Li Q, Ma HJ, Zhang H, Qi Z, Guan Y, Zhang Y. Electrophysiological effects of anandamide on rat myocardium. Br J Pharmacol 2009;158(8):2022-9.
47. Yun J, Yoon KS, Lee TH, Lee H, Gu SM, Song YJ, Cha HJ, Han KM, Seo H, Shin J and others. Synthetic cannabinoid, JWH-030, induces QT prolongation through hERG channel inhibition. Toxicol Res (Camb) 2016;5(6):1663-1671.
48. Hancox JC, Kalk NJ, Henderson G. Synthetic cannabinoids and potential cardiac arrhythmia risk: an important message for drug users. Ther Adv Drug Saf 2020;11:2042098620913416.
49. McKeever RG, Vearrier D, Jacobs D, LaSala G, Okaneku J, Greenberg MI. K2–not the spice of life; synthetic cannabinoids and ST elevation myocardial infarction: a case report. J Med Toxicol 2015;11(1):129-31.
50. Heath TS, Burroughs Z, Thompson AJ, Tecklenburg FW. Acute intoxication caused by a synthetic cannabinoid in two adolescents. J Pediatr Pharmacol Ther 2012;17(2):177-81.
51. Paul ABM, Simms L, Amini S, Paul AE. Teens and Spice: A Review of Adolescent Fatalities Associated with Synthetic Cannabinoid Use. J Forensic Sci 2018;63(4):1321-1324.
52. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005;8(5):585-9.
53. Carai MA, Colombo G, Maccioni P, Gessa GL. Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. CNS Drug Rev 2006;12(2):91-9.
54. Cooper ZDJCpr. Adverse effects of synthetic cannabinoids: management of acute toxicity and withdrawal. 2016;18(5):1-10.
55. Dalton VS, Wang H, Zavitsanou K. HU210-induced downregulation in cannabinoid CB1 receptor binding strongly correlates with body weight loss in the adult rat. Neurochem Res 2009;34(7):1343-53.
56. Ashino T, Hakukawa K, Itoh Y, Numazawa S. Inhibitory effect of synthetic cannabinoids on CYP1A activity in mouse liver microsomes. J Toxicol Sci 2014;39(6):815-20.
57. Chimalakonda KC, James LP, Radominska-Pandya A, Moran JH. Sulfaphenazole and α-naphthoflavone attenuate the metabolism of the synthetic cannabinoids JWH-018 and AM2201 found in K2/spice. Drug Metab Lett 2013;7(1):34-8.
58. Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One 2011;6(7):e21917.
59. Rajasekaran M, Brents LK, Franks LN, Moran JH, Prather PL. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicol Appl Pharmacol 2013;269(2):100-8.
60. Uchiyama N, Kikura-Hanajiri R, Ogata J, Goda Y. Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int 2010;198(1-3):31-8.
61. Wintermeyer A, Möller I, Thevis M, Jübner M, Beike J, Rothschild MA, Bender K. In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. Anal Bioanal Chem 2010;398(5):2141-53.
62. White CM. The Pharmacologic and Clinical Effects of Illicit Synthetic Cannabinoids. J Clin Pharmacol 2017;57(3):297-304.
63. Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 2014;144:12-41.